Relay Therapeutics, Inc.
RLAY · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $588,616 | $1,349,568 | $1,676,771 | $2,921,649 |
| - Cash | $124,287 | $143,736 | $151,794 | $280,119 |
| + Debt | $48,502 | $53,466 | $57,742 | $22,900 |
| Enterprise Value | $512,831 | $1,259,298 | $1,582,719 | $2,664,430 |
| Revenue | $10,007 | $25,546 | $1,381 | $3,029 |
| % Growth | -60.8% | 1,749.8% | -54.4% | – |
| Gross Profit | $10,007 | $25,546 | $1,381 | $3,029 |
| % Margin | 100% | 100% | 100% | 100% |
| EBITDA | -$380,210 | -$374,153 | -$306,822 | -$223,082 |
| % Margin | -3,799.4% | -1,464.6% | -22,217.4% | -7,364.9% |
| Net Income | -$337,708 | -$341,973 | -$290,509 | -$363,872 |
| % Margin | -3,374.7% | -1,338.7% | -21,036.1% | -12,012.9% |
| EPS Diluted | -2.36 | -2.79 | -2.59 | -3.82 |
| % Growth | 15.4% | -7.7% | 32.2% | – |
| Operating Cash Flow | -$249,107 | -$300,316 | -$229,490 | -$74,406 |
| Capital Expenditures | -$2,018 | -$4,126 | -$9,062 | -$3,471 |
| Free Cash Flow | -$251,125 | -$304,442 | -$238,552 | -$77,877 |